Bayer AG Standardizes on Veeva Vault Clinical Applications Globally
23.7.2020 14:03:00 EEST | Business Wire | Press release
Veeva Systems (NYSE:VEEV) today announced that Bayer AG (ETR:BAYN) has selected Veeva Vault Study Startup and Veeva Vault eTMF globally to accelerate site activation and improve visibility across trials.
“Veeva cloud applications will enable us to streamline trial execution,” said Joerg Moeller, Head of Pharma R&D at Bayer AG. “We appreciate Veeva’s modern technology and customer-centric approach to partnership.”
Veeva will enable Bayer AG to manage clinical content and data on a single cloud platform to unify their operations. Vault Study Startup streamlines end-to-end study start-up processes from site identification to site greenlight. Vault eTMF enables active TMF management for real-time visibility and control, helping life sciences companies meet compliance regulations to stay inspection ready.
Bringing both these applications together will enable Bayer AG’s clinical teams to eliminate manual processes, share the same trial documents, and automatically file content from Vault Study Startup in Vault eTMF.
“Life sciences companies are adopting Veeva Vault Clinical applications to speed study execution as they manage a growing number of clinical trials,” said Rik Van Mol, vice president of strategy for Veeva Development Cloud. “Now Bayer AG will be able to have a complete view of trial documents from study activation to study close, while maintaining a constant state of inspection readiness.”
Vault Study Startup and Vault eTMF are part of the Veeva Vault Clinical Suite, the industry’s first cloud platform that includes CDMS, Study Startup, eTMF, CTMS, and Payments to unify clinical data management and clinical operations. Veeva’s suite of unified applications provides global visibility into trial activities and streamlines end-to-end clinical processes.
Learn more about Veeva Vault Clinical Suite at the upcoming Veeva R&D and Quality Summit, October 13-14, 2020. The virtual event is only open to life sciences industry professionals. Register and stay up-to-date on program details at veeva.com/R&DSummit. Also, watch the on-demand presentations from Veeva R&D and Quality Summit, Europe at veeva.com/EUSummit.
Additional Information
For more on Veeva Vault Clinical Suite, visit: veeva.com/Clinical
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 875 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended April 30, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
® 2020 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200723005073/en/
Contact information
Roger Villareal
Veeva Systems
925-264-8885
roger.villareal@veeva.com
Kiran May
Veeva Systems
+44-796-643-2912
kiran.may@veeva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ParaScript Acquired by Stakk to Create a Global Digital Trust Platform Focused on Combating Fraud24.9.2026 15:30:00 EEST | Press release
ParaScript, an Al-powered document processing company, today announced that Stakk Limited (ASX: SKK) (“Stakk”), a company publicly traded on the Australian Stock Exchange (ASX), has successfully completed its US$63 million (A$88.7 million) acquisition of ParaScript, LLC and ParaScript Management, Inc. (“ParaScript”), creating a scaled and profitable AI-native digital trust platform. Stakk acquired ParaScript for its industry-leading AI-powered document processing and recognition technology, which uses advanced machine learning to process large volumes of documents with high speed and accuracy, helping organizations detect fraud earlier, prevent losses and improve outcomes. The combined business becomes one of the largest AI-native digital trust infrastructures serving regulated industries, with more than 300 enterprise customers and more than 110 billion digital interactions processed annually across the U.S., Europe, the Middle East and Australia. Customers include many of the world's
SLB Awarded Four Multi-Year Integrated Well Construction Contracts by Aramco24.9.2026 15:04:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) today announced it has been awarded four integrated well construction contracts by Aramco to support oil and gas development across the Kingdom of Saudi Arabia. Under the contracts, SLB will manage end-to-end well construction services, delivering more than 450 wells in the three-year term, with an optional extension of up to two years. "Delivering hundreds of wells across a multi-year program and in multiple operating environments requires an integrated model that connects planning, execution, and digital workflows to set new industry performance benchmarks,” said Steve Gassen, executive vice president of Geographies for SLB. “Awarding SLB these advanced well construction programs at scale reflects Aramco’s confidence in our integrated model and capabilities." SLB's integrated well construction model brings together every aspect of well delivery through a technology-enabled operating model. It combines digital drilling workflows with au
Sahajanand Medical Technologies Receives EU MDR Certification for Supraflex Cruz and Product Family, Reinforcing Global Compliance and Patient Safety24.9.2026 15:03:00 EEST | Press release
Sahajanand Medical Technologies Limited (SMT), a leading global manufacturer of cardiovascular medical devices, today announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family. SMT is a leading player in India’s drug-eluting stent market and ranks among the top five companies in key European markets, including Germany, Spain and Poland. The certification follows the conformity assessment process established under EU MDR 2017/745 including assessment of SMT’s technical documentation, clinical evaluation and quality management system. Together with SMT’s existing ISO 13485 quality management system and MDSAP certifications, the EU MDR certification confirms that Supraflex Cruz has successfully undergone assessment against the EU MDR’s stringent requirements for safety, performance and clinical evidence. Supraflex Cruz is a sirolimus-eluting coronary stent system designed to improve luminal d
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)24.9.2026 14:00:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions subscales (SAPS-H+D), once daily 60 mg remlifanserin demonstrated a change of -12.6 versus a -10.4 change for placebo at week 6, yielding a standardized effect size of 0.26 (p=0.0603). For the key secondary endpoint, Clinical Global Impression – Severity (CGI-S-ADP), the 60 mg dose achieved a change from baseline of -1.3 versus a change of -0.9 for placebo at week 6, yielding a standardized effect size of 0.37 [p=0.0077 (nominal)]. On both efficacy measures, the difference in the 60 mg dose versus placebo increased through the 6-week treatment period. The 30 mg dose showe
Arthur D. Little GEMRIX 2026 Report: The EV TRANSITION is Now an Ecosystem Race, With China Setting the Global Pace24.9.2026 13:15:00 EEST | Press release
Ecosystem, not vehicle technology is now decisive in electric vehicle (EV) adoption, and is responsible for sharp differences between markets. This is the key finding of Arthur D. Little (ADL)'s 2026 Global Electric Mobility Readiness Index (GEMRIX), which shows where ecosystems are ready and where structural gaps hold EVs back. China and Norway have both passed the point where EVs have achieved parity with internal combustion engine (ICE) vehicles. The most comprehensive study of its kind, the third edition of GEMRIX assesses 31 markets across five dimensions: macro factors, EV market/competition, customer readiness, public charging infrastructure, total cost of ownership and regulation. A score of 100 indicates broad market-readiness parity between EVs and ICE vehicles. The study highlights three global conclusions: A small group has pulled ahead. China (106) and Norway (103) are the only markets above 100; Singapore (96) and the Netherlands (90) follow closely. Sustained adoption co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom